The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Sep 2012
Randomized Controlled Trial Multicenter Study Comparative StudySubcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
A subcutaneous formulation of trastuzumab has been developed, offering potential improvements in patient convenience and resource use compared with the standard intravenous infusion of the drug. We compared the pharmacokinetic profile, efficacy, and safety of the subcutaneous and intravenous formulations in patients with HER2-positive early breast cancer. ⋯ F Hoffmann-La Roche.